Targeted therapies in the management of colorectal carcinoma: Role of bevacizumab

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 1-15

  Puthillath, Ajithkumar ^a   Patel, Anush ^b   Fakih, Marwan G ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Bevacizumab; Colorectal cancer; Fluorouracil; Irinotecan; Metastatic; Oxaliplatin

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CELECOXIB; CETUXIMAB; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MAGNESIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PANITUMUMAB; PLACEBO; VASCULOTROPIN;

ADD ON THERAPY; ADJUVANT THERAPY; AGING; ANGIOGENESIS; ARTERIAL THROMBOEMBOLISM; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CARCINOMA; DIARRHEA; DIET SUPPLEMENTATION; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MENTAL HEALTH; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SURGICAL INFECTION; SURGICAL WOUND; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION; VENOUS THROMBOEMBOLISM; WOUND DEHISCENCE; WOUND HEALING;

EID: 77049088724     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Jemal A Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
2. Ries LAG, Melbert D, et al. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
3. Cancer.net. Colorectal Cancer - Overview.Available at http://www. cancer.net/patient/Cancer+Types/Colorectal+Cancer. In.
4. Sanoff HK, Sargent DJ, Campbell ME, et al. N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC). J Clin Oncol. (Meeting Abstracts) 2007;25(18 suppl):4067.
5. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-2947 (Pubitemid 30644117)
6. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041-1047 (Pubitemid 30162806)
7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905-914 (Pubitemid 30727802)
8. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25(30):4779-4786 (Pubitemid 350086481)
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342 (Pubitemid 38702844)
10. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345 (Pubitemid 38944402)
11. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first Line. J Clin Oncol. 2005;23(36):9441-9442 (Pubitemid 46260214)
12. Fidler IJ Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185-188 (Pubitemid 24324908)
13. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186
14. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676
15. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol. 2001;280(6):C1358-66.
16. Dvorak HF. Discovery of vascular permeability factor (VPF). Exp Cell Res. 2006;312(5):522-526
17. Nagy JA, Vasile E, Feng D, et al. VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol. 2002;67:227-237 (Pubitemid 36775516)
18. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med. 2003;13(5):169-175
19. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368-4380
20. Tanaka K, Yamaguchi S, Sawano A, Shibuya M. Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase). Jpn J Cancer Res. 1997;88(9):867-876 (Pubitemid 27475089)
21. Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem. 1998;273(47):31283-31288 (Pubitemid 28533144)
22. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci. 2003;94(9):751-756 (Pubitemid 37258771)
23. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Func. 2001;26(1):25-35. (Pubitemid 32421949)
24. Shibuya M. [Involvement of the VEGF-Flt-receptor family in angio-genesis]. Nippon Yakurigaku Zasshi. 1996;107(3):119-131
25. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem. 1998;273(47):31273-31282 (Pubitemid 28533143)
26. Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem. 2003;278(49):48848-48860
27. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92(6):735-745 (Pubitemid 28155313)
28. Soker S. Neuropilin in the midst of cell migration and retraction. Int J Biochem Cell Biol. 2001;33(4):433-437 (Pubitemid 32324009)
29. Halder JB, Zhao X, Soker S, et al. Differential expression of VEGF isoforms and VEGF(164)-specific receptor neuropilin-1 in the mouse uterus suggests a role for VEGF(164) in vascular permeability and angiogenesis during implantation. Genesis. 2000;26(3):213-224 (Pubitemid 30194548)
30. Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res. 2008;147(1):99-107. (Pubitemid 351626074)
31. Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer. 1996;78(2):226-231 (Pubitemid 26234563)
32. Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst. 1996;88(16):1110-1117 (Pubitemid 26274605)
33. Logan-Collins JM, Lowy AM, Robinson-Smith TM, et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol. 2008;15(3):738-744
34. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000;36(6):748-753 (Pubitemid 30179746)
35. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res. 1996;56(4):921-924 (Pubitemid 26055486)
36. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-844 (Pubitemid 23132159)
37. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995;95(4):1789-1797
38. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105(8):R15-24. (Pubitemid 30217701)
39. Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19):5565-5570 (Pubitemid 30761274)
40. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 2001;61(1):39-44. (Pubitemid 32095696)
41. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19(3):851-856 (Pubitemid 32119101)
42. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19(3):843-850 (Pubitemid 32119100)
43. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30(5 Suppl 16):117-124
44. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427-434 (Pubitemid 36910021)
45. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23(31):8033-8040 (Pubitemid 46657405)
46. Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007;14(8):2367-2376 (Pubitemid 47174913)
47. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(1):60-65
48. Kopetz S, Glover KY, Eng C, et al. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. J Clin Oncol. (Meeting Abstracts) 2007;25(18 suppl):4089.
49. Sobrero A, Ackland S, Carrion RP, et al. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol. (Meeting Abstracts) 2006;24(18 suppl):3544.
50. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008;26(4):689-690 (Pubitemid 351264373)
51. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25(30):4779-4786 (Pubitemid 350086481)
52. Ackland SP, Clarke S, Perez-Carrión R, et al. Updated efficacy data from AVIRI: A large phase IV trial of first-line bevacizumab plus FOLFIRI in patients with mCRC. Gastrointestinal Cancers Symposium 2008;Orlando; 2008. Abstract No:463.
53. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30.
54. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol. 2008;26(21):3523-3529
55. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013-2019
56. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-1544
57. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23(16):3697-3705 (Pubitemid 46252464)
58. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR Study. J Clin Oncol. 2006;24(3):394-400. (Pubitemid 46630458)
59. Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol. (Meeting Abstracts) 2008;26(15 suppl):4010.
60. Berry SR, Van Cutsem E, Kretzschmar A, et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. J Clin Oncol. (Meeting Abstracts) 2008;26(15 suppl):4025.
61. Grothey A, Sugrue M, Hedrick E, et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). J Clin Oncol. (Meeting Abstracts) 2007;25(18 suppl):4036.
62. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006;24(21):3354-3360 (Pubitemid 46638889)
63. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345 (Pubitemid 38944402)
64. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658-1664 (Pubitemid 46797944)
65. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000;6(9):3739-3747 (Pubitemid 30694960)
66. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer. 2002;38(8):1133-1140 (Pubitemid 34468020)
67. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer. 2001;85(4):584-589 (Pubitemid 32808285)
68. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25(29):4557-4561
69. Hecht JR, Mitchell E, Chidiac T, et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). 2008 Gastrointestinal Cancers Symposium Orlando. Abstract No: 273.
70. Hecht JR, Mitchell E, Chidiac T, et al. Interim results from PACCE: Irinotecan (Iri)/bevacizumab (bev) ± panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC). 2008 Gastrointestinal Cancers Symposium. Abstract No:279.
71. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol. (Meeting Abstracts) 2008;26(15 suppl):LBA4011.
72. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol. (Meeting Abstracts) 2008;26(15 suppl):4000.
73. Van Cutsem E, Lang I, D'Haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol. (Meeting Abstracts) 2008;26(15 suppl):2.
74. A randomized, three arm multinational phase III study to investigate bevacizumab (q3w or q2w) in combination with either intermittent capecitabine plus oxaliplatin (XELOX) (q3w) or fluorouracil/leucovorin with oxaliplatin (FOLFOX-4) versus FOLFOX-4 regimen alone as adjuvant chemotherapy in colon carcinoma. Accessed on August 21 at http://www.clinicaltrials.gov/ct2/show/ NCT00112918?term=AVANT &rank=1.
75. A phase III clinical trial comparing infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (mFOLFOX6) every two weeks with bevacizumab to the same regimen without bevacizumab for the treatment of patients with resected stages II and III carcinoma of the colon. Accessed Aug 2008 at http://www.clinicaltrials.gov/ct2/show/NCT00096278?term=NSABP+C-08&rank=1.
76. A randomized phase III study comparing 5-FU, leucovorin and oxaliplatin versus 5-FU, leucovorin, oxaliplatin and bevacizumab in patients with stage II colon cancer at high risk for recurrence to determine prospectively the prognostic value of molecular markers. 2008. Accessed August 1st, 2008, at http://www.clinicaltrials.gov/ct2/show/NCT00217737?term=E5202&rank=1.
77. Giantonio BJ CP, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 25:1539-1544
78. A multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer. 2008. (Accessed August 1st, 2008, at http://www.octo-oxford.org.uk/alltrials/trials/q2.html.
79. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Wolmark N. Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. J Clin Oncol. (Meeting Abstracts) 2008;26(15 suppl):4006.
80. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23(16):3706-3712 (Pubitemid 46252465)
81. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23(16):3706-3712 (Pubitemid 46252465)
82. Shen B-Q, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem. 1999;274(46):33057-33063 (Pubitemid 129535347)
83. Morere JF, Des Guetz G, Mourad J, Levy BI, Breau J. Mechanism of bevacizumab-induced arterial hypertension: Relation with skin capillary rarefaction in patients treated for metastatic colorectal cancer. J Clin Oncol. (Meeting Abstracts) 2007;25(18 suppl):3557.
84. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19(5):927-934
85. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186-193 (Pubitemid 46178407)
86. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(1):60-65
87. Genentech. Avastin (bevacizumab) prescribing information. 2006.
88. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;69 Suppl 3:25-33. (Pubitemid 41680950)
89. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol. 2006;33(5 Suppl 10):S26-34. (Pubitemid 44634007)
90. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol. (Meeting Abstracts) 2006;24(18 Suppl):3510.
91. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999;56(3):794-814. (Pubitemid 29411709)
92. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232-1239
93. Hambleton J, Novotny WF, Hurwitz H, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol. (Meeting Abstracts) 2004;22 suppl 14:3528.
94. Kozloff MF, Sugrue MM, Purdie DM, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study. J Clin Oncol. (Meeting Abstracts) 2008;26(15 suppl):4026.
95. Skillings JR, Johnson DH, Miller K, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol. (Meeting Abstracts) 2005;23(16 suppl):3019.
96. Flynn PJ, Sugrue MM, Purdie DM, et al. Serious bleeding events are uncommon in patients (pts) with netastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE Observational Cohort Study. Gastrointestinal Cancers Symposium. 2008; Abstract 346.
97. Purdie DM, Berlin JD, Flynn PJ, et al. The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS). J Clin Oncol. (Meeting Abstracts) 2008;26(15 suppl):4103.
98. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152(6):1445-1452 (Pubitemid 28275003)
99. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Wound healing/ bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. J Clin Oncol. (Meeting Abstracts) 2004;22 14 suppl:3702.
100. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91(3):173-180 (Pubitemid 41254420)
101. Sugrue MM, Purdie DM, Flynn PJ, et al. Serious wound healing complications (WHCs) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE Observational Cohort Study. Gastrointestinal Cancers Symposium. 2008; Abstract No 450.
102. Sugrue MM, Purdie DM, Feng S, et al. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS). J Clin Oncol. (Meeting Abstracts) 2008;26(15 suppl):4105.
103. Berry S KA, Cunningham D. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/ bleeding complications - Preliminary results from first BEAT. Gastrointestinal Cancers Symposium, San Francisco; 2006. p. 208.
104. Sugrue M, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol. (Meeting Abstracts) 2006;24(18 suppl):3535.
105. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007;14(6):1860-1869 (Pubitemid 46870935)
106. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumabassociated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19(3):577-582 (Pubitemid 351325682)
107. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500.
108. Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J 2001;77(903):24-.
109. Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS, 2006. Accessed July 28, 2008, at http://ctep. cancer.gov/forms/ CTCAEv3.pdf.